Biocept Inc  

(Public, NASDAQ:BIOC)   Watch this stock  
Find more results for BIOC
-0.32 (-17.49%)
After Hours: 1.50 -0.01 (-0.66%)
Jan 18, 6:10PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.47 - 1.82
52 week 0.74 - 5.64
Open 1.78
Vol / Avg. 4.20M/3.77M
Mkt cap 23.14M
P/E     -
Div/yield     -
EPS -2.64
Shares 17.50M
Beta     -
Inst. own 19%
Mar 7, 2017
Q4 2016 Biocept Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 9, 2016
Q3 2016 Biocept Inc Earnings Call
Nov 9, 2016
Q3 2016 Biocept Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -452.90% -2779.02%
Operating margin -441.90% -2690.69%
EBITD margin - -2647.83%
Return on average assets -396.93% -197.64%
Return on average equity - -976.31%
Employees 42 -
CDP Score - -


5810 Nancy Ridge Dr Ste 150
SAN DIEGO, CA 92121-2840
United States - Map
+1-858-3208200 (Phone)
+1-858-3208225 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

Officers and directors

Michael W. Nall President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Timothy C. Kennedy Chief Financial Officer and Senior Vice President of Operations
Bio & Compensation  - Reuters
Lyle J. Arnold Ph. D. Senior Vice President - Research & Development, Chief Scientific Officer
Age: 68
Bio & Compensation  - Reuters
Veena Singh M.D. Senior Vice President, Senior Medical Director
Age: 40
Bio & Compensation  - Reuters
Raaj Trivedi Vice President - Commercial Operations
Age: 42
Bio & Compensation  - Reuters
David S. Moskowitz Vice President - Strategy and Corporate Communications
Age: 52
Bio & Compensation  - Reuters
David F. Hale Non-Executive Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
M. Faye Wilson CPA, Lead Independent Director
Age: 77
Bio & Compensation  - Reuters
Marsha A. Chandler Ph.D. Independent Director
Age: 69
Bio & Compensation  - Reuters
Bruce E. Gerhardt CPA Independent Director
Age: 63
Bio & Compensation  - Reuters